(RTTNews) - Next Cure Inc. (NXTC) outlined steady clinical and operational momentum across its two antibody-drug conjugate programs while reporting a preliminary year-end cash position that supports ...

We've always said we believe our payload can be attached to many different types of antigen targets and molecules and create a library or pipeline of ADC molecules. And so this is the power of the ...

Oversubscribed financing led by Jeito Capital, including additional new investment from Vida Ventures, BPI France, and EIFO, with participation from all existing investors Proceeds to support the ...

Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to ...

MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life ...

Sutro Biopharma, Inc. announced a strategic shift in its focus towards its next-generation antibody drug conjugate (ADC) portfolio following a strategic review, reprioritizing its pipeline to ...

Greetings. Welcome to Sutro Biopharma R&D Day 2025 Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Jane Chung, CEO.

Proceeds from the financing will support the advancement of three first- and best-in-class ADC programs through upcoming key clinical milestones While oncology continues to face substantial and ...

Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...